Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks

cancer

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update.

The clinical stage biotechnology company received an FDA Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with Bristol-Myers Squibb Co.’s (NYSE:BMY) Opdivo (nivolumab) for advanced melanoma.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.